From Tech Transfer to Commercialization optimizing Turnaround Time(TAT) in CDMO projects at piramal pharma

Faculty Mentor: Akshay Kumar Mishra(IIHMR University)
Industry Mentor: Shilpy singh(Genral Manager)

Name: Shweta Kumari
Roll No: 0713
Stream: MBA PM-16

About Company

With a focus on Contract Development and Manufacturing (CDMO), Piramal Pharma Solutions provides comprehensive services ranging from drug development to commercialization. With robust capabilities in process development, technology transfer, and regulatory compliance, it helps international pharmaceutical partners expedite time-to-market while maintaining operational excellence and quality

Vision

To deliver sustainable value to patients and stakeholders through innovation' and quality

Mission

Delivering superior, cutting-edge pharmaceutical solutions that improve global health outcomes is Piramal Pharma's mission

Organization Structure



Major learning's from internship

Internship Overview

Issue Statement: Piramal's Tech Transfer (TT) projects take longer than expected because of a lack of digital integration, delays in licensing, QC testing, and documentation. Identifying bottlenecks in the TT lifecycle, conducting root cause analysis of significant delays, suggesting workable solutions, and accelerating commercialization are the goals.

The goals are to Locate bottlenecks in the TT lifecycle; Perform root cause analysis of significant delays; Offer workable solutions; and Quicken commercialization.

SWOT Analysis



Root cause Analysis

Out-of-sequence documentation·Procurement approvals that are delayed AMV repetition and QC backlog (4.5+ months delay Insufficient buffer time and parallel tasking

Gantt Chart



Botleneck identified



Major learning

1.Cross-Functional Coordination:
Timely collaboration across QA, QC, RA, and Manufacturing is key to avoiding delays.
2.Effective Timeline Planning:
Gantt charting with buffer time ensures smoother, more predictable project flo
3.Identifying systemic issues helped reduce turnaround time by 30–40%

Challenges:

1.Delays in QC Involvement Extended timelines and repeated AMVs resulted from QC teams being looped in late.
2.Backlogs of documentation Slow approvals and handovers were caused by manual reviews and non-standard formats

Practical Vs Theoritical

Practical	Theoritical
worked on urgent tech transfer projects with tight deadlines and interdepartmental requirement	Studied about management of projects, how to tackle the problem
Actively collaborated with QA, QC, RA, SCM, and production teams for smooth execution	Learned about organizational behavior, team roles, and coordination models in pharma settings
Identified bottlenecks, proposed solutions like dashboards, standardized templates, and parallel execution	Gained academic knowledge on lean systems, Six Sigma, and process improvement models

Suggestions

1. Include QC at the Outset of the TT Process To prevent AMV delays and resource bottlenecks, include the QC team in the early stages of planning.
2. Put in place centralized project dashboards To increase visibility, track milestones, and close coordination gaps, use real-time trackers.
3. Standardize Templates & Documents To expedite reviews, develop standardized SOPs and checklists for regulatory, AMV, and BMR submissions

TOWS

SO: For quicker tracking, use dashboards and skilled QC.

WO: Reduce delays by automating AMV steps.

ST: Coordinate QC with regulatory schedules.

WT: Standardize documents and include QC as soon as possible.